CA2191733A1 - Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene - Google Patents

Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene

Info

Publication number
CA2191733A1
CA2191733A1 CA002191733A CA2191733A CA2191733A1 CA 2191733 A1 CA2191733 A1 CA 2191733A1 CA 002191733 A CA002191733 A CA 002191733A CA 2191733 A CA2191733 A CA 2191733A CA 2191733 A1 CA2191733 A1 CA 2191733A1
Authority
CA
Canada
Prior art keywords
antibody
cell
cells
agent
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002191733A
Other languages
English (en)
Inventor
Daniel A. Vallera
Bruce R. Blazar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2191733A1 publication Critical patent/CA2191733A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Procédés d'inhibition des réponses des lymphocytes T spécifiques à un antigène qui consistent à utiliser un agent qui inhibe un signal de co-stimulation dans les lymphocytes T. Afin d'inhiber les réponses des lymphocytes T spécifiques à un antigène, on utilise de préférence un premier agent qui inhibe un signal de co-stimulation dans le lymphocyte T (par exemple une protéine de fusion CTLA41g) ainsi qu~un deuxième agent qui inhibe une autre fonction du lymphocyte T, telle que l'adhésion du lymphocyte T à une cellule qui présente un antigène dirigié contre les lymphocytes T. Par exemple, pour inhiber l'adhésion d'un lymphocyte T à une cellule présentant un antigène, on peut utiliser un anticorps anti-LFA-1 associé à une protéine de fusion CTLA41g. De plus, on peut également utiliser un autre agent qui inhibe un signal de co-stimulation dans les lymphocytes T, tel qu'un anticorps anti-B7-1 ou un anticorps anti-B7-2, conjointement avec un deuxième agent qui inhibe un signal de prolifération dans le lymphocyte T, par exemple un anticorps du récepteur anti-IL-2. Ces procédés sont particulièrement utiles pour inhiber la réaction du greffon contre l'hôte et le rejet de tissus ou d'organes transplantés.
CA002191733A 1994-06-07 1995-06-07 Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene Abandoned CA2191733A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25526794A 1994-06-07 1994-06-07
US08/255,267 1994-06-07
US47269795A 1995-06-06 1995-06-06
US08/472,697 1995-06-06

Publications (1)

Publication Number Publication Date
CA2191733A1 true CA2191733A1 (fr) 1995-12-21

Family

ID=26944578

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002191733A Abandoned CA2191733A1 (fr) 1994-06-07 1995-06-07 Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene

Country Status (5)

Country Link
EP (1) EP0784482A2 (fr)
JP (1) JPH10501815A (fr)
AU (1) AU2701895A (fr)
CA (1) CA2191733A1 (fr)
WO (1) WO1995034320A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014865A1 (fr) * 1994-11-10 1996-05-23 Repligen Corporation Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
ATE292689T1 (de) * 1995-05-04 2005-04-15 Us Navy Verbesserte verfahren zur transfektion der t- zellen
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ATE244300T1 (de) * 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
PT892643E (pt) * 1996-03-20 2002-09-30 Univ Emory Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
ES2133085B1 (es) * 1996-12-30 2000-04-01 Hospital Universitario Virgen Metodo de analisis del rechazo agudo en trasplante ortotopico de higado mediante la determinacion de la intensidad de expresion de las moleculas coestimuladoras (cd28, ctla-4, cd80 y cd86) en la superficie de linfocitos de sangre periferica por citometria de flujo.
US7235653B2 (en) 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO1998056417A1 (fr) * 1997-06-11 1998-12-17 The United States Of America, Represented By The Secretary Of The U.S. Department Of The Navy Composition et procede pour prevenir des rejets de greffe ou d'autres reponses immunitaires non adaptives des lymphocytes t
AU746825B2 (en) * 1998-02-04 2002-05-02 Brigham And Women's Hospital Costimulatory blockade and mixed chimerism in allotransplantation
US6841347B1 (en) 1998-02-05 2005-01-11 The General Hospital Corporation In vivo construction of DNA libraries
CN101239185A (zh) 1998-03-17 2008-08-13 中外制药株式会社 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
AU5906099A (en) * 1998-09-04 2000-03-27 Baylor College Of Medicine T cell peptides as therapeutics for immune-related disease
EP1144010B1 (fr) * 1999-01-08 2007-04-18 Wisconsin Alumni Research Foundation Prévention du rejet chronique de greffe par une combinaison d'immunotoxines et de bloqueurs de la costimulation
CN1360596A (zh) 1999-02-12 2002-07-24 遗传研究所有限公司 与b7分子发生反应的人源化免疫球蛋白及应用该免疫球蛋白的治疗方法
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6541608B1 (en) 1999-02-23 2003-04-01 Baylor College Of Medicine T cell receptor Vβ-Dβ-Jβ sequence and methods for its detection
PL364917A1 (en) 1999-02-23 2004-12-27 Baylor College Of Medicine T cell receptor vbeta-dbeta-jbeta sequence and methods for its detection
DK1176981T3 (da) 1999-05-07 2006-04-10 Genentech Inc Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001068134A2 (fr) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Therapies permettant d'ameliorer la survie d'un greffon
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
WO2001095928A2 (fr) 2000-06-09 2001-12-20 Bristol-Myers Squibb Company Procedes de regulation de reponse immunitaire a mediation cellulaire au moyen du blocage des signaux lymphocytaires et du blocage de l'adhesion induite par l'antigene lfa-1
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
KR100864120B1 (ko) 2000-07-03 2008-10-16 브리스톨-마이어스스퀴브컴파니 가용성 ｃｔｌａ4 분자를 사용한 류마티스성 질환의 치료법
EP1334731B1 (fr) 2000-10-25 2008-02-27 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
DK1397153T3 (da) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler
US7897582B2 (en) 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
CA2868733C (fr) * 2004-03-22 2019-12-17 Mesoblast International Sarl Cellules souches mesenchymateuses destinees au traitement de l'inflammation
EP1954311A4 (fr) 2005-12-07 2009-12-23 Medarex Inc Régimes d'escalade de dose d'anticorps ctla-4
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
KR101398713B1 (ko) 2005-12-20 2014-06-12 브리스톨-마이어스 스큅 컴퍼니 조성물 및 조성물의 제조 방법
US20090169522A1 (en) 2006-01-13 2009-07-02 Alla Danilkovitch Mesenchymal stem cells expressing tnf-a receptor
EP2624845A4 (fr) 2010-10-08 2015-09-09 Mesoblast Internat S Rl Préparations de msc renforcées
EP3898688A1 (fr) * 2018-12-18 2021-10-27 Catapult Therapeutics B.V. Utilisation de mabs anti-ccr7 pour la prévention ou le traitement d'une maladie du greffon contre l'hôte (gvhd)
WO2020172391A1 (fr) * 2019-02-22 2020-08-27 The Children's Medical Center Méthodes et compositions se rapportant au traitement de la gvhd
IL294921A (en) 2020-01-24 2022-09-01 Pfizer Antibodies against E-selectin, preparations and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500788A (ja) * 1993-07-26 1997-01-28 ダナ・ファーバー・キャンサー・インスティテュート・インコーポレイテッド Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター

Also Published As

Publication number Publication date
EP0784482A2 (fr) 1997-07-23
WO1995034320A3 (fr) 1996-01-18
JPH10501815A (ja) 1998-02-17
AU2701895A (en) 1996-01-05
WO1995034320A2 (fr) 1995-12-21

Similar Documents

Publication Publication Date Title
CA2191733A1 (fr) Procedes d'inhibition des reponses des lymphocytes t specifiques a un antigene
JP6879910B2 (ja) Ｃａｒｔ細胞における遺伝子発現の改変およびその使用
US11648270B2 (en) Methods for treating chronic lymphocytic leukemia (CLL)
ES2354156T3 (es) Activación y expansión de células t.
DE69533984T2 (de) Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat
Haspot et al. Anti‐CD28 Antibody‐Induced Kidney Allograft Tolerance Related to Tryptophan Degradation and TCR− Class II− B7+ Regulatory Cells
US20080305092A1 (en) Methods of treating autoimmune disease via CTLA-4IG
US20060286089A1 (en) Compositions and methods for the treatment of burns and sepsis
JP2007126481A (ja) Ｔ細胞の不応答性を調節する方法
TW200403340A (en) Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
JP2006514024A (ja) Ｎｋ細胞の増殖に対する効果を有する医薬組成物及びそれを使用する方法
Murray et al. Dermal microvascular injury in the human peripheral blood lymphocyte reconstituted-severe combined immunodeficient (HuPBL-SCID) mouse/skin allograft model is T cell mediated and inhibited by a combination of cyclosporine and rapamycin
DE69535713T2 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
WO1996014865A1 (fr) Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse
CA2410786A1 (fr) Procede immunotherapeutique permettant de prevenir le rejet de cellules insulaires
Zhai et al. The CD154-CD40 T cell costimulation pathway is required for host sensitization of CD8+ T cells by skin grafts via direct antigen presentation
US20060233795A1 (en) Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cells
Shiohara et al. Differential expression of lymphocyte function-associated antigen 1 (LFA-1) on epidermotropic and non-epidermotropic T-cell clones
AU779289B2 (en) Methods for restoring or enhancing T-cell immune surveillance following naturally or artifically induced immunosuppression
CA2258082A1 (fr) Vaccins cellulaires immunotherapeutiques et leurs procedes de preparation
WO2006052660A2 (fr) Blocage du recepteur il-7 pour supprimer l'immunite
AU748561B2 (en) Methods for inhibiting antigen specific T cell responses
WO2004087876A2 (fr) Utilisation de globules rouges pour faciliter l'activation cellulaire
Tan The role of 4-1BB costimulation in the regulation of T cell responses
Crawford Human peripheral blood dendritic cells: phenotype, morphology, and function

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead